| Oct 24 |
iTeos Therapeutics to Highlight Inupadenant Preclinical, Translational, and Phase 2 A2A-005 Clinical Trial Data in 2L NSCLC at ESMO Immuno-Oncology Congress
|
| Sep 16 |
Nuvalent Flies On 'Multibillion-Dollar' Potential, While Iteos Crashes On Patient Deaths
|
| Sep 16 |
Crude Oil Surges Over 1%; Instil Bio Shares Plunge
|
| Sep 16 |
Why Exicure Shares Are Trading Higher By Over 49%; Here Are 20 Stocks Moving Premarket
|
| Sep 16 |
ESMO 2024: TIGIT race tightens with first look at GSK/iTeos’s TIGIT in NSCLC
|
| Sep 15 |
iTeos Therapeutics: ESMO Data Showing Signs Of A Real Win For TIGIT
|
| Sep 14 |
TIGIT drug from iTeos shrinks lung tumors in trial
|
| Sep 14 |
GSK, iTeos lung cancer therapy outperforms Jemperli in mid-stage trial
|
| Sep 14 |
iTeos Announces Clinically Meaningful Objective Response Rate Observed at Every Dose in Follow-up Interim Analysis of GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients
|
| Aug 28 |
iTeos to Participate in Upcoming Investor Conferences
|
